CN113226374A - 含氨氯地平、氯噻酮和醛固酮受体拮抗剂的药物组合物 - Google Patents

含氨氯地平、氯噻酮和醛固酮受体拮抗剂的药物组合物 Download PDF

Info

Publication number
CN113226374A
CN113226374A CN202080007379.2A CN202080007379A CN113226374A CN 113226374 A CN113226374 A CN 113226374A CN 202080007379 A CN202080007379 A CN 202080007379A CN 113226374 A CN113226374 A CN 113226374A
Authority
CN
China
Prior art keywords
pharmaceutical composition
amlodipine
chlorthalidone
spironolactone
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080007379.2A
Other languages
English (en)
Other versions
CN113226374B (zh
Inventor
陈光亮
于多
白洁
陈平
田敏卿
徐希平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Aosa Pharmed Co ltd
AUSA PHARMED Ltd
Original Assignee
Shenzhen Aosa Pharmed Co ltd
AUSA PHARMED Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Aosa Pharmed Co ltd, AUSA PHARMED Ltd filed Critical Shenzhen Aosa Pharmed Co ltd
Publication of CN113226374A publication Critical patent/CN113226374A/zh
Application granted granted Critical
Publication of CN113226374B publication Critical patent/CN113226374B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明提供一种治疗难治性高血压的药物组合物,由氨氯地平、氯噻酮和醛固酮受体拮抗剂组成。本发明提供的药物组合物针对难治性高血压患者，尤其是低肾素/醛固酮正常或低肾素/醛固酮升高型的难治性高血压患者提供一种有效的降压药物,同时本发明提供的药物组合物还可加强对难治性高血压患者靶器官的保护作用，降低脑血管事件危险性。

Description

PCT国内申请，说明书已公开。

Claims (23)

  1. PCT国内申请，权利要求书已公开。
CN202080007379.2A 2019-02-21 2020-02-19 含氨氯地平、氯噻酮和醛固酮受体拮抗剂的药物组合物 Active CN113226374B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910130538.7A CN111588857A (zh) 2019-02-21 2019-02-21 含氨氯地平、氯噻酮和醛固酮受体拮抗剂的药物组合物
CN2019101305387 2019-02-21
PCT/CN2020/075789 WO2020169041A1 (zh) 2019-02-21 2020-02-19 含氨氯地平、氯噻酮和醛固酮受体拮抗剂的药物组合物

Publications (2)

Publication Number Publication Date
CN113226374A true CN113226374A (zh) 2021-08-06
CN113226374B CN113226374B (zh) 2023-01-24

Family

ID=72144151

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910130538.7A Pending CN111588857A (zh) 2019-02-21 2019-02-21 含氨氯地平、氯噻酮和醛固酮受体拮抗剂的药物组合物
CN202080007379.2A Active CN113226374B (zh) 2019-02-21 2020-02-19 含氨氯地平、氯噻酮和醛固酮受体拮抗剂的药物组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201910130538.7A Pending CN111588857A (zh) 2019-02-21 2019-02-21 含氨氯地平、氯噻酮和醛固酮受体拮抗剂的药物组合物

Country Status (2)

Country Link
CN (2) CN111588857A (zh)
WO (1) WO2020169041A1 (zh)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103565813A (zh) * 2012-07-24 2014-02-12 刘超 一种抗高血压药物增效剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070287690A1 (en) * 2006-06-08 2007-12-13 Lawrence Solomon Compositions and methods comprising a thiazide diuretic and a mineralocorticoid inhibitor
CN101450211A (zh) * 2007-12-07 2009-06-10 上海艾力斯医药科技有限公司 复方降压制剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103565813A (zh) * 2012-07-24 2014-02-12 刘超 一种抗高血压药物增效剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
王翔凌等: "难治性高血压", 《中国心血管杂志》 *

Also Published As

Publication number Publication date
CN111588857A (zh) 2020-08-28
CN113226374B (zh) 2023-01-24
WO2020169041A1 (zh) 2020-08-27

Similar Documents

Publication Publication Date Title
KR101493016B1 (ko) 중약 조성물의 새로운 용도
US6391867B2 (en) Use of spironolactone for treatment of symptomatic heart failure
KR20040104632A (ko) 호르몬 대체 요법을 받는 여성에서 고혈압의 치료
CN108635511B (zh) 一种以白芍和铁皮石斛制备治疗高血压药物的方法
CN116887826A (zh) 治疗与s1p1受体相关的病症的方法
CN111840112B (zh) 鼠尾草酸或其衍生物在制备治疗糖尿病并发症药物中的应用
EP2837380B1 (en) Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof
CN113226374B (zh) 含氨氯地平、氯噻酮和醛固酮受体拮抗剂的药物组合物
JPH11507012A (ja) 心臓血管系病気の処置におけるアンギオテンシン変換酵素阻害薬と副作用軽減量のアルドステロン拮抗薬との組合わせ治療
CN115243774B (zh) 含氨氯地平、氯噻酮和阿米洛利的药物组合物
WO2006105726A1 (fr) Composition pour le traitement de l’hypertension
WO2014187185A1 (zh) 一种药物组合物作为制备治疗皮炎湿疹中的应用
EP3804705B1 (en) Pharmaceutical composition for preventing diabetes and use thereof
CN113616651B (zh) 一种复方降压药物组合物及其应用
CN111450255A (zh) 一种缓解睡眠-呼吸暂停综合征的药物组合物及其制备方法
CN104744404A (zh) 稳定的氢氯噻嗪晶体化合物、其复方马来酸依那普利药物组合物
KR20190043076A (ko) 암로디핀, 로자탄 및 로수바스타틴을 포함하는 당뇨병을 동반한 심혈관계 질환의 예방 또는 치료용 약학 조성물 및 이를 포함하는 복합제제
CN102335177B (zh) 一种口服固体药用组合物及其制备方法
JP5982715B2 (ja) 抗高血圧薬組成物
Isles et al. A randomised double-blind study comparing nifedipine GITS 20 mg and bendrofluazide 2.5 mg administered once daily in mild-to-moderate hypertension
Standard Pr AURO-LOSARTAN
CN116098960A (zh) 一种治疗慢性心力衰竭的中药组合物及其制备方法、用途
CN110237258A (zh) 用于治疗高血压的药物组合物
WO2021224494A1 (en) New treatments of viral infections
CN102552399B (zh) 一种清热平肝的中药组合物及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant